Key facts
- This page summarizes Robert Canarick's Form 4 filing for INTEGRATED BIOPHARMA INC (INBP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 25 Jun 2026, 11:29.
Robert Canarick - 24 Jun 2026 Form 4 Insider Report for INTEGRATED BIOPHARMA INC (INBP)
- Reporting relationship
- Director
- Issuer ticker
- INBP
- Reported as of
- 24 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Jun 2026, 11:29:15 UTC
- Prior SEC filing
- 20 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Canarick
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert Canarick filed Form 4 for INTEGRATED BIOPHARMA INC (INBP) on 25 Jun 2026.
Change
- Previous filing in this sequence was filed on 20 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001382218
Primary reporting owner
Canarick Robert
- Relationship
- Director
- Address
- C/O INTEGRATED BIOPHARMA, INC., 225 LONG AVENUE, BLDG 15, HILLSIDE
- Signature
- /s/ Robert Canarick
- Signature date
- 25 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INBP
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +50,000
- Change %
- Price
- $0.000000*
- Shares after
- 50,000
- Date
- 24 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $0.1900
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027.